(Q30641273)

25 June 2017

1 reference

title

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development (English)

1 reference

25 June 2017

1 reference

Cutler NR

1

1 reference

PubMed ID

11263756

25 June 2017

Sramek JJ

series ordinal

2

1 reference

25 June 2017

1 January 2001

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

25 June 2017

1 reference

25 June 2017

25

1 reference

25 June 2017

1

1 reference

25 June 2017

27-57

1 reference

Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E.

25 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Expression and regulation of cyclooxygenase-2 in rat microglia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Vitamin E protects nerve cells from amyloid beta protein toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Alpha-2 macroglobulin is genetically associated with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

MRI of entorhinal cortex in mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

17 beta-Estradiol enhances the outgrowth and survival of neocortical neurons in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A case-control study of Alzheimer's disease in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Indomethacin and cognitive function in healthy elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Curing amyloidosis: will it work in humans?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Prospects for pharmacological intervention in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Estimated prevalence of Alzheimer's disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Pharmacology and efficacy of cyclooxygenase (COX) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Platelet monoamine oxidase B activity in dementia. A 4-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Immunization with beta-amyloid: could T-cell activation have a harmful effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The presenilins in Alzheimer's disease--proteolysis holds the key.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type).

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in cultured cortical neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The five-five, ten-ten plan for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Modulation byDLST of the genetic risk of Alzheimer's disease in a very elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The clinical potential of cyclooxygenase-2-specific inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Indomethacin-induced behavioral changes in an elderly patient with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians, and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Alzheimer disease: protective factors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Dementia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Low plasma vitamin C in Alzheimer patients despite an adequate diet.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Epidemiology of clinically diagnosed Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Indomethacin is inappropriate for use in the geriatric population.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidative activities: 17 alpha-substituted analogs of delta 9(11)-dehydro-17 beta-estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Molecular genetics of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Increased lipoprotein oxidation in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

1 reference

7 January 2021

Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

The Women’s Health Initiative Memory Study (WHIMS)

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Ongoing trials in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Megatrials of hormonal replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900147-0

7 January 2021

10.1016/S0278-5846(00)00147-0

Identifiers

DOI

1 reference

25 June 2017

1 reference

PubMed ID

11263756